Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30. https://doi.org/10.1056/NEJMOA1412082/SUPPL_FILE/NEJMOA1412082_DISCLOSURES.PDF.
Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13. https://doi.org/10.1056/NEJMOA1510665/SUPPL_FILE/NEJMOA1510665_DISCLOSURES.PDF.
Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–26. https://doi.org/10.1056/NEJMOA1613683.
Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–67. https://doi.org/10.1056/NEJMOA1602252.
Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33. https://doi.org/10.1056/NEJMOA1606774.
Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182–91. https://doi.org/10.1016/S1470-2045(17)30422-9.
Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563–80. https://doi.org/10.1038/s41571-019-0218-0.
Wongvibulsin S, Pahalyants V, Kalinich M, et al. Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: a United States population-level analysis. J Am Acad Dermatol. 2022;86(3):563–72. https://doi.org/10.1016/J.JAAD.2021.03.094.
Han Y, Wang J, Xu B. Cutaneous adverse events associated with immune checkpoint blockade: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021. https://doi.org/10.1016/J.CRITREVONC.2021.103376.
Yoest JM. Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review. Immunotargets Ther. 2017;6:73. https://doi.org/10.2147/ITT.S126227.
Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science. 1995;270(5238):985–8. https://doi.org/10.1126/SCIENCE.270.5238.985.
Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11(2):141–51. https://doi.org/10.1016/S1074-7613(00)80089-8.
Sandigursky S, Mor A. Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. Curr Rheumatol Rep. 2018. https://doi.org/10.1007/S11926-018-0770-0.
Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3(5):541–7. https://doi.org/10.1016/1074-7613(95)90125-6.
Hua C, Boussemart L, Mateus C, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 2016;152(1):45–51. https://doi.org/10.1001/JAMADERMATOL.2015.2707.
Huang SKS, Okamoto T, Morton DL, Hoon DSB. Antibody responses to melanoma/melanocyte autoantigens in melanoma patients. J Investig Dermatol. 1998;111(4):662–7. https://doi.org/10.1046/J.1523-1747.1998.00354.X.
Flatz L, Berner F, Bomze D, et al. Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer. JAMA Oncol. 2019;5(7):1. https://doi.org/10.1001/JAMAONCOL.2019.0402.
Root-Bernstein R, Fairweather DL. Unresolved issues in theories of autoimmune disease using myocarditis as a framework. J Theor Biol. 2015;375:101. https://doi.org/10.1016/J.JTBI.2014.11.022.
Quach HT, Johnson DB, LeBoeuf NR, Zwerner JP, Dewan AK. Cutaneous adverse events caused by immune checkpoint inhibitors. J Am Acad Dermatol. 2021;85(4):956–66. https://doi.org/10.1016/J.JAAD.2020.09.054.
National Cancer Institute. Common terminology criteria for adverse events (CTCAE) common terminology criteria for adverse events (CTCAE) v5.0. Published online 2017. https://www.meddra.org/. Accessed 29 Nov 2021.
Thompson JA, Schneider BJ, Brahmer J, et al. NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2020;18(3):230–41. https://doi.org/10.6004/JNCCN.2020.0012.
Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021. https://doi.org/10.1200/JCO.21.01440.
Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv119–42. https://doi.org/10.1093/ANNONC/MDX225.
Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9(6):2435. https://doi.org/10.1136/JITC-2021-002435.
Nadelmann ER, Yeh JE, Chen ST. Management of cutaneous immune-related adverse events in patients with cancer treated with immune checkpoint inhibitors: a systematic review. JAMA Oncol. 2021. https://doi.org/10.1001/JAMAONCOL.2021.4318.
Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5(1):95. https://doi.org/10.1186/S40425-017-0300-Z.
Barrios DM, Phillips GS, Freites-Martinez A, et al. Outpatient dermatology consultations for oncology patients with acutedermatologic adverse events impact anticancer therapy interruption: aretrospective study. J Eur Acad Dermatol Venereol. 2020;34(6):1340. https://doi.org/10.1111/JDV.16159.
Chen ST, Molina GE, Lo JA, et al. Dermatology consultation reduces interruption of oncologic management among hospitalized patients with immune-related adverse events: a retrospective cohort study. J Am Acad Dermatol. 2020;82(4):994–6. https://doi.org/10.1016/J.JAAD.2019.09.026.
Thompson LL, Li EB, Krasnow NA, et al. Effect of dermatological consultation on survival in patients with checkpoint inhibitor-associated cutaneous toxicity. Br J Dermatol. 2021;185(3):627–35. https://doi.org/10.1111/BJD.20074.
Gerstein W, Gniadecki R. Cutaneous immune-related adverse events (irAEs) to immune checkpoint inhibitors: a dermatology perspective on management. J Cutan Med Surg. 2021;25(1):59–76. https://doi.org/10.1177/1203475420943260.
Naing A, Hajjar J, Gulley JL, et al. Strategies for improving the management of immune-related adverse events. J Immunother Cancer. 2020;8(2): e001754. https://doi.org/10.1136/JITC-2020-001754.
Esfahani K, Elkrief A, Calabrese C, et al. Moving towards personalized treatments of immune-related adverse events. Nat Rev Clin Oncol. 2020;17(8):504–15. https://doi.org/10.1038/S41571-020-0352-8.
Martins F, Obeid M. Personalized treatment of immune-related adverse events—balance is required. Nat Rev Clin Oncol. 2020;17(8):517. https://doi.org/10.1038/s41571-020-0400-4.
Ortonne N, Valeyrie-Allanore L, Bastuji-Garin S, et al. Histopathology of drug rash with eosinophilia and systemic symptoms syndrome: a morphological and phenotypical study. Br J Dermatol. 2015;173(1):50–8. https://doi.org/10.1111/BJD.13683.
Ellis SR, Vierra AT, Millsop JW, Lacouture ME, Kiuru M. Dermatologic toxicities to immune checkpoint inhibitor therapy: a review of histopathologic features. J Am Acad Dermatol. 2020;83(4):1130. https://doi.org/10.1016/J.JAAD.2020.04.105.
Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714–68. https://doi.org/10.1200/JCO.2017.77.6385.
Ibraheim H, Perucha E, Powell N. Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors. Rheumatology (Oxford). 2019;58(Suppl. 7):vii17. https://doi.org/10.1093/RHEUMATOLOGY/KEZ465.
Gault A, Anderson AE, Plummer R, Stewart C, Pratt AG, Rajan N. Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors. Br J Dermatol. 2021;185(2):263–71. https://doi.org/10.1111/BJD.19750.
Apalla Z, Rapoport B, Sibaud V. Dermatologic immune-related adverse events: the toxicity spectrum and recommendations for management. Int J Womens Dermatol. 2021;7(5 Part A):625–35. https://doi.org/10.1016/J.IJWD.2021.10.005.
Hashimoto H, Ito T, Ichiki T, Yamada Y, Oda Y, Furue M. The clinical and histopathological features of cutaneous immune-related adverse events and their outcomes. J Clin Med. 2021;10(4):1–13. https://doi.org/10.3390/JCM10040728.
Elgart ML. Cutaneous sarcoidosis: definitions and types of lesions. Clin Dermatol. 1986;4(4):35–45. https://doi.org/10.1016/0738-081X(86)90032-5.
Yanardag H, Tetikkurt C, Bilir M, Demirci S, Iscimen A. Diagnosis of cutaneous sarcoidosis; clinical and the prognostic significance of skin lesions. Multidiscip Respir Med. 2013;8(3):1–6. https://doi.org/10.1186/2049-6958-8-26/TABLES/4.
Geisler AN, Phillips GS, Barrios DM, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020;83(5):1255–68. https://doi.org/10.1016/J.JAAD.2020.03.132.
Siegel J, Totonchy M, Damsky W, et al. Bullous disorders associated with anti-PD-1 and anti–PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. J Am Acad Dermatol. 2018;79(6):1081–8. https://doi.org/10.1016/J.JAAD.2018.07.008.
Gonçalo MM, Cardoso JC, Gouveia MP, et al. Histopathology of the exanthema in DRESS is not specific but may indicate severity of systemic involvement. Am J Dermatopathol. 2016;38(6):423–33. https://doi.org/10.1097/DAD.0000000000000439.
Uemura M, Faisal F, Haymaker C, et al. A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1. J Immunother Cancer. 2016. https://doi.org/10.1186/S40425-016-0157-6.
Koelzer VH, Buser T, Willi N, et al. Grover’s-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy. J Immunother Cancer. 2016. https://doi.org/10.1186/S40425-016-0151-Z.
Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, version 1.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2019;17(3):255–89. https://doi.org/10.6004/JNCCN.2019.0013.
Ingen-Housz-Oro S, Milpied B, Badrignans M, et al. Severe blistering eruptions induced by immune checkpoint inhibitors: a multicentre international study of 32 cases. Melanoma Res. 2022;32(3):205–10. https://doi.org/10.1097/CMR.0000000000000819.
Lesage C, Longvert C, Prey S, et al. Incidence and clinical impact of anti-TNFα treatment of severe immune checkpoint inhibitor-induced colitis in advanced melanoma: the Mecolit Survey. J Immunother. 2019;42(5):175–9. https://doi.org/10.1097/CJI.0000000000000268.
Montfort A, Dufau C, Colacios C, et al. Anti-TNF, a magic bullet in cancer immunotherapy? J Immunother Cancer. 2019;7(1):1–4. https://doi.org/10.1186/S40425-019-0802-Y/FIGURES/1.
Montfort A, Colacios C, Levade T, Andrieu-Abadie N, Meyer N, Ségui B. The TNF paradox in cancer progression and immunotherapy. Front Immunol. 2019;10(July):1818. https://doi.org/10.3389/FIMMU.2019.01818/BIBTEX.
Charles KA, Kulbe H, Soper R, et al. The tumor-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Investig. 2009;119(10):3011–23. https://doi.org/10.1172/JCI39065.
Phillips GS, Wu J, Hellmann MD, et al. Treatment outcomes of immune-related cutaneous adverse events. J Clin Oncol. 2019;37(30):2746–58. https://doi.org/10.1200/JCO.18.02141.
Voudouri D, Nikolaou V, Laschos K, et al. Anti-PD1/PDL1 induced psoriasis. Curr Probl Cancer. 2017;41(6):407–12. https://doi.org/10.1016/J.CURRPROBLCANCER.2017.10.003.
del Rosso JQ, Kim GK. The rationale behind topical vitamin D analogs in the treatment of psoriasis: where does topical calcitriol fit in? J Clin Aesthet Dermatol. 2010;3(8):46.
Trémezaygues L, Reichrath J. Vitamin D analogs in the treatment of psoriasis: where are we standing and where will we be going? Dermatoendocrinology. 2011;3(3):180. https://doi.org/10.4161/DERM.3.3.17534.
Weinstein GD, Koo JYM, Krueger GG, et al. Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol. 2003;48(5):760–7. https://doi.org/10.1067/MJD.2003.103.
Angelo JS, Kar BR, Thomas J. Comparison of clinical efficacy of topical tazarotene 0.1% cream with topical clobetasol propionate 0.05% cream in chronic plaque psoriasis: a double-blind, randomized, right-left comparison study. Indian J Dermatol Venereol Leprol. 2007;73(1):65. https://doi.org/10.4103/0378-6323.30663.
Fallon JD, Sober A. Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. J Am Acad Dermatol. 1994;31(4):613–6. https://doi.org/10.1016/S0190-9622(94)70225-X.
Amatore F, Villani A-P, Tauber M, Viguier M, Guillot B, Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie). French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol. 2019;33(3):464–83. https://doi.org/10.1111/JDV.15340.
Perez-Ruiz E, Minute L, Otano I, et al. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature. 2019;569(7756):428–32. https://doi.org/10.1038/S41586-019-1162-Y.
Kaye A, Gordon SC, Deverapalli SC, Her MJ, Rosmarin D. Dupilumab for the treatment of recalcitrant bullous pemphigoid. JAMA Dermatol. 2018;154(10):1225–6. https://doi.org/10.1001/JAMADERMATOL.2018.2526.
Zhang Y, Xu Q, Chen L, et al. Efficacy and safety of dupilumab in moderate-to-severe bullous pemphigoid. Front Immunol. 2021;12:4144. https://doi.org/10.3389/FIMMU.2021.738907/BIBTEX.
Jolles S, Sewell WAC, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol. 2005;142(1):1. https://doi.org/10.1111/J.1365-2249.2005.02834.X.
Malviya N, Tattersall IW, Leventhal J, Alloo A. Cutaneous immune-related adverse events to checkpoint inhibitors. Clin Dermatol. 2020;38(6):660–78. https://doi.org/10.1016/J.CLINDERMATOL.2020.06.011.
Eskin-Schwartz M, David M, Mimouni D. Mycophenolate mofetil for the management of autoimmune bullous diseases. Dermatol Clin. 2011;29(4):555–9. https://doi.org/10.1016/J.DET.2011.06.012.
Nousari HC, Sragovich A, Kimyai-Asadi A, Orlinsky D, Anhalt GJ. Mycophenolate mofetil in autoimmune and inflammatory skin disorders. J Am Acad Dermatol. 1999;40(2):265–8. https://doi.org/10.1016/S0190-9622(99)70203-3.
Shen J, Chang J, Mendenhall M, Cherry G, Goldman JW, Kulkarni RP. Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management. Ther Adv Med Oncol. 2018. https://doi.org/10.1177/1758834017751634.
Birnbaum MR, Ma MW, Fleisig S, et al. Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma. JAAD Case Rep. 2017;3(3):208–11. https://doi.org/10.1016/J.JDCR.2017.02.015.
Sowerby L, Dewan AK, Granter S, Gandhi L, LeBoeuf NR. Rituximab treatment of nivolumab-induced bullous pemphigoid. JAMA Dermatol. 2017;153(6):603–5. https://doi.org/10.1001/JAMADERMATOL.2017.0091.
Ito J, Fujimoto D, Nakamura A, et al. Aprepitant for refractory nivolumab-induced pruritus. Lung Cancer. 2017;109:58–61. https://doi.org/10.1016/J.LUNGCAN.2017.04.020.
Barrios DM, Phillips GS, Geisler AN, et al. IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies. Ann Oncol. 2021;32(6):736–45. https://doi.org/10.1016/J.ANNONC.2021.02.016.
Kouwenhoven TA, van de Kerkhof PCM, Kamsteeg M. Use of oral antidepressants in patients with chronic pruritus: a systematic review. J Am Acad Dermatol. 2017;77(6):1068-73.e7. https://doi.org/10.1016/J.JAAD.2017.08.025.
Kaur R, Sinha VR. Antidepressants as antipruritic agents: a review. Eur Neuropsychopharmacol. 2018;28(3):341–52. https://doi.org/10.1016/J.EURONEURO.2018.01.007.
Yeo B, Tey HL. Effective treatment of notalgia paresthetica with amitriptyline. J Dermatol. 2013;40(6):505–6. https://doi.org/10.1111/1346-8138.12154.
Davis MP, Frandsen JL, Walsh D, Andresen S, Taylor S. Mirtazapine for pruritus. J Pain Symptom Manag. 2003;25(3):288–91. https://doi.org/10.1016/S0885-3924(02)00645-0.
Shohrati M, Davoudi SM, Keshavarz S, Sadr B, Tajik A. Cetirizine, doxepine, and hydroxyzine in the treatment of pruritus due to sulfur mustard: a randomized clinical trial. Cutan Ocul Toxicol. 2008;26(3):249–55. https://doi.org/10.1080/15569520701212340.
Eggermont AMM, Kicinski M, Blank CU, et al. Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2020;6(4):519–27. https://doi.org/10.1001/JAMAONCOL.2019.5570.
Baldini E, Lunghi A, Cortesi E, et al. Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: the Italian NSCLC expanded access program. Lung Cancer. 2020;140:59–64. https://doi.org/10.1016/J.LUNGCAN.2019.12.014.
Gerber DE, Hsiehchen D, Watters MK, Lu R, Xie Y. Variation in the assessment of immune-related adverse event occurrence, grade, and timing in patients receiving immune checkpoint inhibitors. JAMA Netw Open. 2019;2(9): e1911519. https://doi.org/10.1001/JAMANETWORKOPEN.2019.11519.
Abu-Sbeih H, Ali FS, Naqash AR, et al. Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis. J Clin Oncol. 2019;37(30):2738. https://doi.org/10.1200/JCO.19.00320.
Pollack MH, Betof A, Dearden H, et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol. 2018;29(1):250. https://doi.org/10.1093/ANNONC/MDX642.
Allouchery M, Lombard T, Martin M, et al. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer. J Immunother Cancer. 2020;8(2): e001622. https://doi.org/10.1136/JITC-2020-001622.
Zhao Q, Zhang J, Xu L, et al. Safety and efficacy of the rechallenge of immune checkpoint inhibitors after immune-related adverse events in patients with cancer: a systemic review and meta-analysis. Front Immunol. 2021. https://doi.org/10.3389/FIMMU.2021.730320/FULL.
Inno A, Roviello G, Ghidini A, et al. Rechallenge of immune checkpoint inhibitors: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021;165: 103434. https://doi.org/10.1016/J.CRITREVONC.2021.103434.
Santini FC, Rizvi H, Plodkowski AJ, et al. Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC. Cancer Immunol Res. 2018;6(9):1093–9. https://doi.org/10.1158/2326-6066.CIR-17-0755.
Dolladille C, Ederhy S, Sassier M, et al. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol. 2020;6(6):865–71. https://doi.org/10.1001/JAMAONCOL.2020.0726.
Haanen J, Ernstoff M, Wang Y, et al. Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. J Immunother Cancer. 2020;8(1):604. https://doi.org/10.1136/JITC-2020-000604.
Albandar HJ, Fuqua J, Albandar JM, Safi S, Merrill SA, Ma PC. Immune-related adverse events (irAE) in cancer immune checkpoint inhibitors (ICI) and survival outcomes correlation: to rechallenge or not? Cancers (Basel). 2021;13(5):1–15. https://doi.org/10.3390/CANCERS13050989.
Shah P, Boland P, Pavlick AC. Response to immune checkpoint inhibitor (ICI) rechallenge after high-grade immune related adverse events (irAE) in patients (pts) with metastatic melanoma (MM). J Clin Oncol. 2020;38(15_Suppl):10045. https://doi.org/10.1200/JCO.2020.38.15_SUPPL.10045.
Ravi P, Mantia C, Su C, et al. Evaluation of the safety and efficacy of immunotherapy rechallenge in patients with renal cell carcinoma. JAMA Oncol. 2020;6(10):1606–10. https://doi.org/10.1001/JAMAONCOL.2020.2169.
Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908–18. https://doi.org/10.1016/S1470-2045(15)00083-2.
Inno A, Lo Russo G, Salgarello M, et al. The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: from Karnofsky to iRECIST. Tumori. 2018;104(2):88–95. https://doi.org/10.1177/0300891618766173.
Prior LM, Harrold E, O’Leary CG, et al. Toxicities in immunotherapy: can they predict response? https://doi-org.proxy.library.vanderbilt.edu/101200/JCO20163415_suppl.e14534. 2016;34(15_Suppl.):e14534. https://doi.org/10.1200/JCO.2016.34.15_SUPPL.E14534. Accessed 4 June 2022.
Suo A, Chan Y, Beaulieu C, et al. Anti-PD1-induced immune-related adverse events and survival outcomes in advanced melanoma. Oncologist. 2020;25(5):438–46. https://doi.org/10.1634/THEONCOLOGIST.2019-0674.
Park BC, Stone CA, Dewan AK, Johnson DB. Hypersensitivity reactions and immune-related adverse events to immune checkpoint inhibitors: approaches, mechanisms, and models. Immunol Allergy Clin N Am. 2022;42(2):285–305. https://doi.org/10.1016/J.IAC.2021.12.006.
Zhang Q, Vignali DAA. Co-stimulatory and co-inhibitory pathways in autoimmunity. Immunity. 2016;44(5):1034–51. https://doi.org/10.1016/J.IMMUNI.2016.04.017.
Zamani MR, Aslani S, Salmaninejad A, Javan MR, Rezaei N. PD-1/PD-L and autoimmunity: a growing relationship. Cell Immunol. 2016;310:27–41. https://doi.org/10.1016/J.CELLIMM.2016.09.009.
Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. https://doi.org/10.1056/NEJMOA1003466/SUPPL_FILE/NEJMOA1003466_DISCLOSURES.PDF.
Haanen J, Ernstoff MS, Wang Y, et al. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. Ann Oncol. 2020;31(6):724–44. https://doi.org/10.1016/J.ANNONC.2020.03.285.
Khan SA, Pruitt SL, Xuan L, Gerber DE. Prevalence of autoimmune disease among patients with lung cancer: implications for immunotherapy treatment options. JAMA Oncol. 2016;2(11):1507–8. https://doi.org/10.1001/JAMAONCOL.2016.2238.
Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;157(8):940–6. https://doi.org/10.1001/JAMADERMATOL.2021.2007.
Bergqvist C, Ezzedine K. Vitiligo: a review. Dermatology. 2020;236(6):571–92. https://doi.org/10.1159/000506103.
Wertenteil S, Garg A, Strunk A, Alloo A. Prevalence estimates for pemphigoid in the United States: a sex-adjusted and age-adjusted population analysis. J Am Acad Dermatol. 2019;80(3):655–9. https://doi.org/10.1016/J.JAAD.2018.08.030.
Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann Intern Med. 2018. https://doi.org/10.7326/M17-2073.
Danlos FX, Voisin AL, Dyevre V, et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer. 2018;91:21–9. https://doi.org/10.1016/J.EJCA.2017.12.008.
Tison A, Quéré G, Misery L, et al. Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study. Arthritis Rheumatol. 2019;71(12):2100–11. https://doi.org/10.1002/ART.41068/ABSTRACT.
Halle BR, Betof Warner A, Zaman FY, et al. Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy. J Immunother Cancer. 2021;9(10): e003066. https://doi.org/10.1136/JITC-2021-003066.
Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2(2):234–40. https://doi.org/10.1001/JAMAONCOL.2015.4368.
Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017;28(2):368–76. https://doi.org/10.1093/ANNONC/MDW443.
Engels EA, Pfeiffer RM, Fraumeni JF, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306(17):1891–901. https://doi.org/10.1001/JAMA.2011.1592.
Fisher J, Zeitouni N, Fan W, Samie FH. Immune checkpoint inhibitor therapy in solid organ transplant recipients: a patient-centered systematic review. J Am Acad Dermatol. 2020;82(6):1490–500. https://doi.org/10.1016/J.JAAD.2019.07.005.
Abdel-Wahab N, Safa H, Abudayyeh A, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J Immunother Cancer. 2019;7(1):1–10. https://doi.org/10.1186/S40425-019-0585-1/FIGURES/1.
Kittai AS, Oldham H, Cetnar J, Taylor M. Immune checkpoint inhibitors in organ transplant patients. J Immunother. 2017;40(7):277–81. https://doi.org/10.1097/CJI.0000000000000180.
Aguirre LE, Guzman ME, Lopes G, Hurley J. Immune checkpoint inhibitors and the risk of allograft rejection: a comprehensive analysis on an emerging issue. Oncologist. 2019;24(3):394. https://doi.org/10.1634/THEONCOLOGIST.2018-0195.
Saberianfar S, Nguyen LS, Manouchehri A, et al. Solid organ transplant rejection associated with immune-checkpoint inhibitors. Ann Oncol. 2020;31(4):543–4. https://doi.org/10.1016/J.ANNONC.2020.01.012.
De Bruyn P, Van Gestel D, Ost P, et al. Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go? Curr Opin Oncol. 2019;31(2):54–64. https://doi.org/10.1097/CCO.0000000000000505.
Wu CK, Juang GD, Lai HC. Tumor regression and preservation of graft function after combination with anti-PD-1 immunotherapy without immunosuppressant titration. Ann Oncol. 2017;28(11):2895–6. https://doi.org/10.1093/ANNONC/MDX409.
Cooper JE. Evaluation and treatment of acute rejection in kidney allografts. Clin J Am Soc Nephrol. 2020;15(3):430–8. https://doi.org/10.2215/CJN.11991019.
KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(Suppl. 3):S1–155. https://doi.org/10.1111/J.1600-6143.2009.02834.X.
ClinicalTrials.gov. Tacrolimus, nivolumab, and ipilimumab in treating kidney transplant recipients with selected unresectable or metastatic cancers: full text view. https://clinicaltrials.gov/ct2/show/NCT03816332. Accessed 29 Nov 2021.